Literature DB >> 7635774

Electron beam therapy is not inferior to superficial x-ray therapy in the treatment of skin carcinoma.

C Griep1, J Davelaar, A N Scholten, A Chin, J W Leer.   

Abstract

PURPOSE: To compare recurrence rates and cosmetic results after electron beam therapy vs. superficial x-ray therapy for nonmelanoma skin carcinoma. METHODS AND MATERIALS: A retrospective analysis was performed on 389 histologically confirmed basal cell and squamous cell carcinomas of the skin, treated with either superficial x-rays or electron beam therapy, with regard to local control rates and cosmetics, as scored with an arbitrary three-point scale.
RESULTS: The overall local recurrence rate was 4.9% (19 out of 389). For small tumors (irradiated surfaces < or = 10 cm2) a local recurrence rate of 2.2% was observed, both after electron beam therapy and after superficial x-ray therapy. Tumor size and previous treatment proved to be important prognostic factors with regard to control rate. The well-fractionated electron beam therapy yielded better cosmetic results than the large fraction superficial x-ray therapy.
CONCLUSION: Electron beam treatment is not inferior to superficial x-ray treatment and even better for larger tumors. The inferior results of electron beam therapy reported in literature might be due to technical factors, which are discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7635774     DOI: 10.1016/0360-3016(94)00603-I

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Predictors of recurrence after radiotherapy for non-melanoma skin cancer.

Authors:  L Khan; D Breen; L Zhang; J Balogh; G Czarnota; J Lee; M N Tsao; E A Barnes
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

2.  Radiotherapy treatment of non-melanoma skin cancer: a survey of current UK practice and commentary.

Authors:  A J McPartlin; N J Slevin; A J Sykes; A Rembielak
Journal:  Br J Radiol       Date:  2014-09-05       Impact factor: 3.039

Review 3.  [Alternative treatment options for periorbital basal cell carcinoma].

Authors:  Vinodh Kakkassery; Steffen Emmert; Irenäus A Adamietz; György Kovács; Anselm M Jünemann; Caroline Otte; Michael Zimbelmann; Anton Brosig; Salvatore Grisanti; Ludwig M Heindl
Journal:  Ophthalmologe       Date:  2020-02       Impact factor: 1.059

Review 4.  [Current diagnostics and therapy recommendations for ocular basal cell carcinoma].

Authors:  V Kakkassery; K U Loeffler; M Sand; K R Koch; A M Lentzsch; A C Nick; I A Adamietz; L M Heindl
Journal:  Ophthalmologe       Date:  2017-03       Impact factor: 1.059

Review 5.  Preservation of form and function in the management of head and neck skin cancer.

Authors:  Michael Poulsen; Bryan Burmeister; Dan Kennedy
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

6.  High-dose-rate (HDR) plesiotherapy with custom-made moulds for the treatment of non-melanoma skin cancer.

Authors:  Angel Montero; Raúl Hernanz; Ana-Belén Capuz; Eva Fernández; Asunción Hervás; Rafael Colmenares; Alfredo Polo; Sonsoles Sancho; Rafael Molerón; Carmen Vallejo; Alfredo Ramos
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

Review 7.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Advances in the management of basal cell carcinoma.

Authors:  Jesse M Lewin; John A Carucci
Journal:  F1000Prime Rep       Date:  2015-05-12

9.  Low-Energy Laser-Driven Ultrashort Pulsed Electron Beam Irradiation-Induced Immune Response in Rats.

Authors:  Gohar Tsakanova; Nelly Babayan; Elena Karalova; Lina Hakobyan; Liana Abroyan; Aida Avetisyan; Hranush Avagyan; Sona Hakobyan; Arpine Poghosyan; Bagrat Baghdasaryan; Elina Arakelova; Violetta Ayvazyan; Lusine Matevosyan; Arpine Navasardyan; Hakob Davtyan; Lilit Apresyan; Arsham Yeremyan; Rouben Aroutiounian; Andreyan N Osipov; Bagrat Grigoryan; Zaven Karalyan
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.